ArticleOpen veterinary journal2025
The protective effect of baicalin against cyclophosphamide-induced testicular damage in rats.
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: Cyclophosphamide (CTX) is a widely used chemotherapeutic agent; however, its clinical application is often limited by significant reproductive toxicity, particularly testicular damage. Baicalin (BAI) has demonstrated broad pharmacological activities, including anti-inflammatory, antioxidant, and anti-apoptotic effects. Aim: To investigate the protective effect of BAI on testicular damage induced by CTX in rats. Methods: Network pharmacology was used to identify the core targets of BAI-testis damage. Animal experiments were conducted using 30 SPF-grade 7-week-old SD rats divided into a control group (Control), a CTX group, a low-dose BAI group (BAI-L), a medium-dose BAI group (BAI-M), and a high-dose BAI group (BAI-H), with six rats in each group. Molecular docking, quantitative polymerase chain reaction, and Western blot were used to validate the core targets of network pharmacology. H&E staining was performed to observe testicular tissue damage. The levels of interleukin-1β, interleukin-10, reactive oxygen species, and malondialdehyde in the testes and the levels of follicle-stimulating hormone, luteinizing hormone, and testosterone in the serum were measured. Immunofluorescence was used to detect germ, supporting, and interstitial cells in the testes. Results: Network pharmacology identified 127 common targets between BAI and testicular damage. BAI acts on Ptgs2, Gsk3b, and Pparg targets. Molecular docking and animal experiments indicated that BAI exhibits strong binding affinity with Ptgs2, Gsk3b, and Pparg. Animal experiments showed that BAI can improve CTX-induced pathological tissue damage, reduce inflammatory responses, and alleviate oxidative stress in rat testes. BAI can repair CTX-induced damage to germ cells, supporting cells, interstitial cells, and repaired reproductive hormones, with the extent of repair showing a dose-dependent relationship. Conclusion: This study demonstrates the beneficial effects of BAI in alleviating CTX-induced reproductive toxicity, and BAI can be used to reduce the side effects of CTX.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.